Laurus Labs Limited (LAURUSLABS.BO)
INR 579.2
(3.34%)
INR 579.2
(3.34%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 3.94 Billion INR | -68.09% |
| 2022 | 13.13 Billion INR | 10.58% |
| 2021 | 11.88 Billion INR | -10.09% |
| 2020 | 13.21 Billion INR | 289.13% |
| 2019 | 3.39 Billion INR | 87.43% |
| 2018 | 1.81 Billion INR | -33.11% |
| 2017 | 2.7 Billion INR | -7.85% |
| 2016 | 2.93 Billion INR | 4.7% |
| 2015 | 2.8 Billion INR | 92.14% |
| 2014 | 1.46 Billion INR | -15.49% |
| 2013 | 1.72 Billion INR | 41.62% |
| 2012 | 1.22 Billion INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 651.4 Million INR | -58.71% |
| 2024 Q2 | 708.2 Million INR | 8.72% |
| 2023 Q3 | 830.1 Million INR | -12.16% |
| 2023 FY | 4.19 Billion INR | -68.09% |
| 2023 Q2 | 945 Million INR | 24.06% |
| 2023 Q1 | 761.7 Million INR | -61.63% |
| 2023 Q4 | 1.57 Billion INR | 90.06% |
| 2022 Q3 | 3.19 Billion INR | -13.06% |
| 2022 Q1 | 3.83 Billion INR | 15.84% |
| 2022 Q4 | 1.98 Billion INR | -37.79% |
| 2022 FY | 13.13 Billion INR | 10.58% |
| 2022 Q2 | 3.67 Billion INR | -4.25% |
| 2021 Q4 | 3.3 Billion INR | 49.58% |
| 2021 Q2 | 2.81 Billion INR | -16.31% |
| 2021 Q3 | 2.21 Billion INR | -21.5% |
| 2021 FY | 11.88 Billion INR | -10.09% |
| 2021 Q1 | 3.36 Billion INR | -18.06% |
| 2020 Q2 | 3.27 Billion INR | 38.62% |
| 2020 Q3 | 3.81 Billion INR | 16.34% |
| 2020 Q4 | 4.11 Billion INR | 7.72% |
| 2020 FY | 13.21 Billion INR | 289.13% |
| 2020 Q1 | 2.36 Billion INR | 80.35% |
| 2019 Q4 | 1.31 Billion INR | 27.94% |
| 2019 Q1 | 419.2 Million INR | -25.38% |
| 2019 Q2 | 913.4 Million INR | 117.89% |
| 2019 Q3 | 1.02 Billion INR | 12.26% |
| 2019 FY | 3.39 Billion INR | 87.43% |
| 2018 Q1 | 449.47 Million INR | -48.54% |
| 2018 FY | 1.81 Billion INR | -33.11% |
| 2018 Q4 | 561.77 Million INR | 21.01% |
| 2018 Q3 | 464.22 Million INR | -0.03% |
| 2018 Q2 | 464.36 Million INR | 3.31% |
| 2017 Q3 | 663.17 Million INR | -25.59% |
| 2017 Q4 | 873.52 Million INR | 31.72% |
| 2017 FY | 2.7 Billion INR | -7.85% |
| 2017 Q1 | 742.7 Million INR | -23.49% |
| 2017 Q2 | 891.21 Million INR | 20.0% |
| 2016 Q1 | 625.52 Million INR | 0.0% |
| 2016 Q4 | 970.74 Million INR | 14.38% |
| 2016 FY | 2.93 Billion INR | 4.7% |
| 2016 Q3 | 848.72 Million INR | -6.32% |
| 2016 Q2 | 905.93 Million INR | 44.83% |
| 2015 FY | 2.8 Billion INR | 92.14% |
| 2014 FY | 1.46 Billion INR | -15.49% |
| 2013 FY | 1.72 Billion INR | 41.62% |
| 2012 FY | 1.22 Billion INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 31.425% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 90.644% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 56.025% |
| Granules India Limited | 6.81 Billion INR | 42.075% |
| Indoco Remedies Limited | 1.29 Billion INR | -205.489% |
| Achyut Healthcare Limited | 4.43 Million INR | -88872.51% |
| Ajanta Pharma Limited | 19.67 Billion INR | 79.933% |
| Alkem Laboratories Limited | 19.46 Billion INR | 79.711% |
| Alpa Laboratories Limited | 184.49 Million INR | -2040.197% |
| Brooks Laboratories Limited | 14.44 Million INR | -27244.875% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | -129.904% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -220.763% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 94.17% |
| Eris Lifesciences Limited | 5.18 Billion INR | 23.798% |
| FDC Limited | 2.98 Billion INR | -32.228% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 39.275% |
| Gufic Biosciences Limited | 1.32 Billion INR | -196.907% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 10.676% |
| Ipca Laboratories Limited | 7.98 Billion INR | 50.523% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -677.085% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 2698.498% |
| Lasa Supergenerics Limited | -458 Million INR | 962.13% |
| Lupin Limited | 28.04 Billion INR | 85.92% |
| Mankind Pharma Limited | 21.51 Billion INR | 81.65% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -3836.79% |
| Megasoft Limited | -121.1 Million INR | 3360.503% |
| NATCO Pharma Limited | 25.96 Billion INR | 84.791% |
| Piramal Pharma Limited | 4.55 Billion INR | 13.349% |
| RPG Life Sciences Limited | 2.29 Billion INR | -72.255% |
| Sigachi Industries Limited | 1.47 Billion INR | -167.902% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 96.214% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 14.303% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -1484.186% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -593.082% |
| Windlas Biotech Limited | 1.29 Billion INR | -203.998% |
| ZIM Laboratories Limited | 253.82 Million INR | -1455.614% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 90.84% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 195.955% |
| Divi's Laboratories Limited | 33.08 Billion INR | 88.063% |
| Hester Biosciences Limited | 364.81 Million INR | -982.372% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -41.73% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -762.999% |
| Bal Pharma Limited | 233.9 Million INR | -1588.092% |
| Strides Pharma Science Limited | 5.22 Billion INR | 24.44% |
| Venus Remedies Limited | 534.65 Million INR | -638.538% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -26.229% |
| Nectar Lifesciences Limited | 923.8 Million INR | -327.427% |
| Shilpa Medicare Limited | 1.36 Billion INR | -189.005% |
| Aarti Drugs Limited | 7.14 Billion INR | 44.765% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | -147.282% |
| Suven Life Sciences Limited | -1.22 Billion INR | 422.119% |
| Ind-Swift Limited | 1.22 Billion INR | -222.081% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 72.354% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 202.484% |
| Themis Medicare Limited | 392.58 Million INR | -905.785% |
| Hikal Limited | 32.11 Million INR | -12197.104% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 84.415% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -530.263% |
| Wockhardt Limited | -670 Million INR | 689.343% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 23.904% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -43440.971% |
| Neuland Laboratories Limited | 5.31 Billion INR | 25.752% |
| Morepen Laboratories Limited | 4.17 Billion INR | 5.396% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -1797.909% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -14280.508% |